Key result
Increased flow-mediated dilatation in AL amyloidosis is linked to ~4.4-fold higher early mortality.
Cohort (n=170)
Answers are grounded in this paper and cite their sources.
Prospective study shows elevated flow-mediated dilatation independently predicts mortality in light-chain amyloidosis, highlighting vascular reactivity as a novel prognostic marker.
Rationale: Cardiac involvement and hypotension dominate the prognosis of light-chain amyloidosis (AL). Evidence suggests that there is also peripheral vascular involvement in AL but its prognostic significance is unknown. Objective: To evaluate vascular dysfunction in patients with AL as a potential future area of intervention, we assessed the prognostic utility of flow-mediated dilatation (FMD), a marker of vascular reactivity, which is augmented under conditions of hypotension and autonomic dysfunction. Methods and Results: We prospectively evaluated 115 newly diagnosed untreated AL patients in whom FMD was measured. FMD in AL patients was significantly higher than age-, sex- and risk factors–matched controls (4.0% versus 2.32%; P =0.006) and comparable with control groups at lower cardiovascular risk ( P >0.1). Amyloidosis patients presented increased plasma and exhaled markers of the NO pathway while their FMD significantly correlated with augmented sustained vasodilatation after sympathetic stimulation. Increased FMD (≥4.5%) was associated with early mortality (hazard ratio, 4.36; 95% CI, 1.41–13.5; P =0.010) and worse survival (hazard ratio, 2.11; 95% CI, 1.17–3.82; P =0.013), even after adjustment for Mayo stage, nerve involvement and low systolic blood pressure. This finding was confirmed in a temporal validation AL cohort (n=55; hazard ratio, 4.2; 95% CI, 1.45–12.3; P =0.008). FMD provided significant reclassification value over the best prognostic model (continuous Net Reclassification Index, 0.61; P =0.001). Finally, better hematologic response was associated with lower posttreatment FMD. Conclusions: FMD is relatively increased in AL and independently associated with inferior survival with substantial reclassification value. Reactive vasodilation merits further investigation as a novel risk biomarker in AL.Visual Overview: An online visual overview is available for this article.
No takes yet. Share an insight, caveat, or question.
Stamatelopoulos et al. (2019) conducted a cohort in Primary systemic light-chain amyloidosis (AL) (n=170). Increased flow-mediated dilatation (FMD ≥4.5%) vs. Lower flow-mediated dilatation (FMD <4.5%) was evaluated on Early mortality (HR 4.36, 95% CI 1.41-13.5, p=0.010). Increased flow-mediated dilatation in light-chain amyloidosis predicted early mortality and worse survival.
Synapse has enriched 10 related papers. Consider them for comparative context: